Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What will become of the German antidiabetics market?

This article was originally published in Scrip

Executive Summary

Yet another company – this time Novo Nordisk – has decided that it wouldn't be good business to sell its antidiabetic in Germany following a rocky ride through the AMNOG benefit assessment and pricing negotiations. While companies are worried about the future of treatments for chronic diseases in Germany, prescribers and health insurers are more sanguine and believe that German patients are not yet missing out on important innovations in the market.

You may also be interested in...



Novo Nordisk CEO Hopes Tresiba Can Re-Enter Germany On A Higher Price

But Novo Nordisk CEO says a DEVOTE-based efficacy price review in Germany analyzing patient sub-groups 'will be a lengthy process'.

German HTA Body Says Well Done On Immuno-Oncology, But Where Are Dementia Breakthroughs?

Germany’s health technology appraisal institute, IQWiG, says that oncology drugs take up more of its time than treatments for any other conditions. And while it welcomes advances in immuno-oncology, it wants to see breakthroughs in other disease areas too.

Germany May Make Drug Prices Confidential In AMNOG Update

Under forthcoming changes to the law, companies could gain confidential pricing in Germany, which could make it easier to defend a higher price in other countries. But sponsor of some orphan products may face a rockier path to market.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC029204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel